A man died in a French hospital on Sunday after taking part in a drug trial for a painkiller based on a compound similar to cannabis.
The Rennes University Hospital announced the death in a statement but did not identify the patient, who had already been in a state of brain death.
He was among six male volunteers between 28 and 49 hospitalised last week after volunteering to take the experimental drug.
French health authorities said three of the hospitalised volunteers face possible brain damage and an investigation is under way into what French health minister Marisol Touraine called "an accident of exceptional gravity".
The trial, which began on January 7, involved 90 healthy volunteers who were given the experimental drug in varying doses at different times.
The hospital said it has contacted the 84 other volunteers exposed to the new painkiller.
Ten of those volunteers underwent medical exams on Saturday but the hospital found no anomalies, the statement says. It said another five will have medical exams closer to their homes.
The drug, based on a natural brain compound similar to the active ingredient in marijuana, was given orally to healthy volunteers as part of a phase one trial by Biotrial, a drug evaluation company based in Rennes, on behalf of the Portuguese pharmaceutical company Bial.
Share article
In addition to treating pain, the drug was intended to ease mood and anxiety troubles as well as motor problems linked to neurodegenerative illnesses by acting on the endocannabinoid system. In this system, natural brain compounds act on specific receptors to exert their effects.
It is rare for volunteers to fall seriously ill during phase one trials, which study safe usage, side effects and other measures on healthy volunteers, rather than drug effectiveness.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here